Skip to main content
Yifeng Pharmacy Chain Co., Ltd. logo

Yifeng Pharmacy Chain Co., Ltd. — Investor Relations & Filings

Ticker · 603939 ISIN · CNE100001TS5 LEI · 300300CZZIF44N1EZO06 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,865 across all filing types
Latest filing 2025-04-28 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 603939

About Yifeng Pharmacy Chain Co., Ltd.

https://www.yfdyf.cn/

Yifeng Pharmacy Chain Co., Ltd. operates as a large-scale retail pharmacy enterprise. The company specializes in the distribution and sale of prescription drugs, over-the-counter medicines, traditional Chinese medicine, nutritional supplements, and medical devices. It utilizes a standardized management system across its extensive network of retail stores to ensure service quality and operational efficiency. Beyond physical retail, the company has developed a comprehensive digital healthcare ecosystem, integrating online-to-offline (O2O) services to provide professional pharmaceutical consultations and health management solutions. Its business model focuses on a "big health" strategy, aiming to provide accessible healthcare products and professional services to a broad consumer base through optimized supply chain logistics and a diversified product portfolio.

Recent filings

Filing Released Lang Actions
2024年度独立董事履职报告 (王红霞)(届满离任)
Board/Management Information Classification · 95% confidence The document is titled as the "2024年度独立董事履职报告（王红霞）" which translates to the "2024 Annual Independent Director's Performance Report (Wang Hongxia)". It details the independent director's duties, attendance at board and committee meetings, communication with auditors, and oversight activities during the 2024 term. The content focuses on governance, compliance with laws and regulations, and the director's evaluation of company operations and internal controls. It is a detailed report on the independent director's role and activities rather than a general annual report or financial statement. This type of document fits best under Board/Management Information (MANG) as it relates to board member duties and governance activities. The document length is 4190 characters, which is consistent with a detailed report but not a full annual report or audit report. There is no indication that this is a call transcript, earnings release, or other categories. Therefore, the classification is MANG with high confidence.
2025-04-28 Chinese
益丰药房未来三年（2025年-2027年）股东回报规划
Notice of Dividend Amount Classification · 90% confidence The document is a detailed plan outlining the company's shareholder return policy for the years 2025 to 2027, including dividend distribution methods, conditions, decision-making mechanisms, and adjustment procedures. It is a forward-looking policy document related to dividends and shareholder returns rather than an announcement of dividend amounts or payment dates. It does not contain financial statements or earnings data, nor is it a report or announcement of voting results. The content focuses on the company's strategic planning for dividends and shareholder returns over multiple years, which fits best under the category of Notice of Dividend Amount (DIV) as it relates to dividend policy and shareholder returns planning.
2025-04-28 Chinese
益丰药房2024年环境、社会与公司治理报告
Environmental & Social Information Classification · 95% confidence The document is titled '2024年度环境、社会及公司治理（ESG）报告' which translates to '2024 Environmental, Social and Governance (ESG) Report'. It contains detailed information about the company's ESG strategy, governance structure, sustainability management, stakeholder communication, and materiality assessment. The content focuses on environmental, social, and governance factors, sustainability goals, and related disclosures. There is no indication that this is an announcement or a brief summary; rather, it is a comprehensive report on ESG matters. According to the filing definitions, a report detailing the company's performance on Environmental, Social, and Governance factors fits the category 'Environmental & Social Information (Code: SR)'. The document length (15,000 characters) and detailed content confirm it is a full report, not an announcement or a certification. Therefore, the appropriate classification is 'SR' with high confidence.
2025-04-28 Chinese
益丰药房关于向银行申请综合授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Yifeng Pharmacy Chain Co., Ltd. regarding its application to banks for a comprehensive credit line totaling up to 1,551,500 million RMB. It details the banks involved, credit limits, and the fact that no collateral is required. The document is dated April 29, 2025, and mentions that the credit application requires approval at the 2024 annual shareholders' meeting. The content focuses on financing activities and credit facilities, without any financial statements or earnings data. The document length is 1887 characters, which is relatively short and is clearly an announcement rather than a full report. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2025-04-28 Chinese
益丰药房第五届监事会第十一次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 11th meeting of the 5th Supervisory Board of Yifeng Pharmacy Chain Co., Ltd. It includes multiple agenda items such as approval of the 2024 Supervisory Board Work Report, the 2024 Annual Report and its summary, the 2024 Financial Final Report, a special report on the use of raised funds, the 2024 Internal Control Evaluation Report, the 2024 Profit Distribution Plan, and the 2025 Q1 Report. The document contains voting results and assurances about the accuracy and completeness of these reports. It is not the reports themselves but a formal announcement of the Supervisory Board's resolutions approving these reports and other corporate matters, intended for submission to the shareholders' meeting. The document length is 4049 characters, which is relatively short and consistent with an announcement rather than the full reports. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is an official announcement of supervisory board meeting resolutions and approvals, not the full reports themselves.
2025-04-28 Chinese
益丰药房关于2024年日常关联交易确认及2025年日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the confirmation of 2024 daily related party transactions and the forecast of 2025 daily related party transactions by the company Yifeng Pharmacy Chain Co., Ltd. It includes details about the board meeting approval, transaction amounts, related parties, pricing policies, and the impact on the company. The document is a formal disclosure of related party transactions and their expected amounts, which is typical for regulatory compliance and shareholder information. It does not contain full financial statements or comprehensive financial performance data, nor is it a report like an annual or interim report. It is not a certification or a short notice about report publication. The document is a regulatory announcement about related party transactions, which fits best under Regulatory Filings (RNS). The document length is 4177 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2025-04-28 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.